TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 NG / 0 UG
Include 002 10 NG / 10 UG
Include 003 100 NG /100 UG
Include 005 300 NG /300 UG
Include 007 1000 NG/1000 UG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 98 86 98 98 98
Early Deaths
Moribund Sacrifice 22 19 24 19 20
Natural Death 8 12 6 10 7
Dosing Accident 1 1 1 2
Survivors
Terminal Sacrifice 22 21 22 24 24
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (53) (53) (53) (52) (49)
Intestine Large, Rectum (53) (53) (53) (53) (50)
Schwannoma Malignant, Metastatic, Vagina 1 (2%) 1 (2%)
Intestine Large, Cecum (53) (53) (53) (52) (49)
Intestine Small, Duodenum (53) (53) (52) (52) (50)
Leiomyoma 2 (4%)
Intestine Small, Jejunum (53) (53) (52) (52) (49)
Leiomyosarcoma 1 (2%)
Intestine Small, Ileum (53) (53) (52) (52) (49)
Liver (53) (53) (52) (52) (51)
Cholangiocarcinoma 4 (8%) 9 (18%)
Cholangiocarcinoma, Multiple 1 (2%) 5 (10%) 21 (41%)
Hemangioma 1 (2%)
Hepatocellular Carcinoma 2 (4%)
Hepatocellular Adenoma 3 (6%) 5 (10%) 11 (22%)
Hepatocellular Adenoma, Multiple 16 (31%)
Hepatocholangioma 2 (4%) 5 (10%)
Hepatocholangioma, Multiple 1 (2%)
Mesentery (47) (47) (46) (47) (42)
Nephroblastoma, Metastatic, Kidney 1 (2%)
Oral Mucosa (12) (11) (25) (30) (36)
Gingival, Squamous Cell Carcinoma 2 (8%) 5 (17%) 8 (22%)
Gingival, Squamous Cell Carcinoma, Multiple 1 (3%)
Pancreas (53) (53) (52) (52) (50)
Acinus, Adenoma 1 (2%) 1 (2%) 3 (6%) 1 (2%)
Acinus, Carcinoma 1 (2%) 1 (2%)
Salivary Glands (53) (51) (52) (50) (52)
Stomach, Forestomach (53) (53) (52) (52) (51)
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (53) (53) (52) (52) (51)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (52) (53) (52)
Heart (53) (52) (52) (53) (52)
Fibrosarcoma, Metastatic, Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (53) (52) (52) (51)
Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (52) (53) (52) (52) (51)
Pheochromocytoma Benign 2 (4%) 1 (2%) 4 (8%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (53) (53) (52) (52) (50)
Adenoma 1 (2%) 1 (2%)
Parathyroid Gland (45) (47) (46) (47) (46)
Adenoma 1 (2%)
Pituitary Gland (53) (53) (53) (52) (52)
Carcinoma 1 (2%)
Pars Distalis, Adenoma 22 (42%) 21 (40%) 17 (32%) 17 (33%) 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (53) (53) (51) (52) (52)
Bilateral, C-Cell, Adenoma 2 (4%) 4 (8%) 4 (8%) 3 (6%)
C-Cell, Adenoma 8 (15%) 10 (19%) 12 (24%) 12 (23%) 7 (13%)
C-Cell, Carcinoma 4 (8%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (53) (53) (53) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Ovary (53) (53) (52) (52) (49)
Granulosa Cell Tumor Malignant 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Uterus (53) (53) (53) (52) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Fibrosarcoma 1 (2%)
Polyp Stromal 5 (9%) 7 (13%) 5 (9%) 6 (12%) 3 (6%)
Polyp Stromal, Multiple 3 (6%) 2 (4%)
Sarcoma 1 (2%)
Sarcoma Stromal 1 (2%)
Schwannoma Malignant 2 (4%)
Schwannoma Malignant, Metastatic, Vagina 1 (2%)
Squamous Cell Carcinoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Cervix, Granular Cell Tumor Benign 1 (2%)
Cervix, Squamous Cell Carcinoma 2 (4%)
Vagina (1) (1) (1) (1)
Schwannoma Malignant 1 (100%) 1 (100%)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Lymph Node (4) (7) (2) (7) (14)
Nephroblastoma, Metastatic, Kidney 1 (14%)
Pancreatic, Nephroblastoma, Metastatic,
Kidney 1 (14%)
Lymph Node, Mandibular (53) (51) (52) (50) (51)
Lymph Node, Mesenteric (53) (53) (52) (52) (49)
Spleen (53) (53) (52) (52) (50)
Thymus (53) (50) (48) (50) (51)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (52) (53) (52)
Adenoma 2 (4%) 1 (2%)
Carcinoma 6 (11%) 4 (8%) 2 (4%) 1 (2%)
Carcinoma, Multiple 2 (4%) 1 (2%) 1 (2%)
Fibroadenoma 27 (51%) 22 (42%) 25 (48%) 25 (47%) 11 (21%)
Fibroadenoma, Multiple 13 (25%) 17 (32%) 15 (29%) 9 (17%) 1 (2%)
Skin (53) (53) (53) (53) (53)
Basal Cell Carcinoma 2 (4%) 1 (2%)
Fibroma 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Fibrosarcoma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Keratoacanthoma 1 (2%)
Lipoma 1 (2%) 1 (2%)
Liposarcoma 1 (2%)
Sarcoma 1 (2%) 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (53) (53) (53) (53) (53)
Skeletal Muscle (1) (1) (1) (1)
Fibrosarcoma, Metastatic, Lung 1 (100%)
Fibrous Histiocytoma 1 (100%)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (52) (52)
Astrocytoma Malignant 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%) 1 (2%)
Granular Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (52) (53) (52)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Cystic Keratinizing Epithelioma 1 (2%) 3 (6%)
Cystic Keratinizing Epithelioma, Multiple 8 (15%)
Fibrous Histiocytoma, Metastatic, Skeletal
Page 5
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Muscle 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Mediastinum, Fibrosarcoma 1 (2%)
Nose (53) (53) (53) (53) (53)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (53) (53) (52) (52)
Harderian Gland (53) (53) (53) (52) (52)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (2%) 3 (6%)
Zymbal's Gland (1) (1)
Adenoma 1 (100%)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (53) (52) (52) (51)
Nephroblastoma 1 (2%) 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Ureter (1) (1) (1) (1)
Urinary Bladder (53) (53) (53) (52) (50)
Nephroblastoma, Metastatic, Kidney 1 (2%)
Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(53) *(53) *(53) *(53) *(53)
Lymphoma Malignant 1 (2%) 2 (4%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 09:51:53
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 51 49 50 50 46
Total Primary Neoplasms 110 106 110 126 121
Total Animals with Benign Neoplasms 49 43 48 46 36
Total Benign Neoplasms 92 85 96 93 73
Total Animals with Malignant Neoplasms 14 18 14 23 37
Total Malignant Neoplasms 18 21 14 33 48
Total Animals with Metastatic Neoplasms 3 5 3 3
Total Metastatic Neoplasm 4 8 6 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------